Prelude Therapeutics Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRLD research report →
About the company
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies.
- CEO
- Krishna Vaddi
- IPO
- 2020
- Employees
- 131
- HQ
- Wilmington, DE, US
Price Chart
- Market Cap
- $279.54M
- P/E
- -4.63
- P/S
- 12.13
- P/B
- 6.73
- EV/EBITDA
- -2.61
- Div Yield
- 0.00%
- Gross Margin
- 97.66%
- Op Margin
- -503.21%
- Net Margin
- -465.30%
- ROE
- -118.24%
- ROIC
- -104.28%
- Revenue
- $12.14M · 73.43%
- Net Income
- $-99,498,000 · 21.76%
- EPS
- $-1.29 · 23.21%
- Op Income
- $-104,566,000
- FCF YoY
- 45.62%
- 52W High
- $5.69
- 52W Low
- $0.75
- 50D MA
- $4.39
- 200D MA
- $2.80
- Beta
- 1.01
- Avg Volume
- 495.29K
Get TickerSpark's AI analysis on PRLD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | BAKER BROS. ADVISORS LP | other | 38,000 |
| Jun 9, 26 | Dorton Katina | other | 38,000 |
| Jun 9, 26 | Babler Martin | other | 38,000 |
| Jun 9, 26 | Bonita David P | other | 38,000 |
| Jun 9, 26 | Sandor Victor | other | 38,000 |
| Jun 9, 26 | FRIEDMAN PAUL A | other | 38,000 |
| May 1, 26 | Morris Charles Q | other | 450,000 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,407,000 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,407,000 |
| Apr 21, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
Our PRLD coverage
Recent articles, reports, and earnings notes.
No research on PRLD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRLD report →Similar companies
Peers in the same neighborhood.